<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00023998</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01863</org_study_id>
    <secondary_id>AOST0121</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <secondary_id>CDR0000068882</secondary_id>
    <nct_id>NCT00023998</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma</brief_title>
  <official_title>A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they
      stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and
      kill them without harming normal cells. Combining monoclonal antibody therapy with
      chemotherapy may kill more tumor cells. Phase II trial to study the effectiveness of
      chemotherapy with or without trastuzumab in treating patients who have metastatic
      osteosarcoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the feasibility and safety of trastuzumab (Herceptin) and chemotherapy in
      patients with HER2-overexpressing (2+ level of expression) metastatic osteosarcoma.

      II. Determine the response rate and 3-year event-free survival of patients treated with this
      regimen.

      III. Determine the cardiac toxicity and late effects of this regimen in these patients.

      IV. Determine the response rate and 3-year event-free survival of poor-risk patients with
      HER2-negative tumors treated with chemotherapy without the addition of trastuzumab.

      OUTLINE: This is a multicenter study. Patients are stratified according to tumor HER2 status
      (positive vs negative).

      Patients receive induction therapy comprising doxorubicin IV over 20 minutes followed by
      cisplatin IV over 4 hours on days 1 and 2 of weeks 1 and 6, and methotrexate IV over 4 hours
      on day 1 of weeks 4, 5, 9, and 10. Patients also receive leucovorin calcium IV or orally
      every 6 hours beginning 24 hours after each methotrexate dose and continuing for at least 10
      doses until methotrexate levels sufficiently decrease. Within 24-36 hours after completion of
      induction therapy, patients receive filgrastim (G-CSF) daily until blood counts recover.

      Patients undergo resection of any remaining primary tumor and/or metastatic lesions during
      week 11. Patients who are unable to undergo resection receive radiotherapy between weeks 11
      and 17.

      Patients receive post-induction therapy comprising doxorubicin IV over 20 minutes on days 1
      and 2 of weeks 17, 25, and 29; cisplatin IV over 4 hours on days 1 and 2 of weeks 17 and 25;
      methotrexate IV over 4 hours on day 1 of weeks 16, 20, 24, 28, 32, and 33; etoposide IV over
      1 hour on days 1-5 of weeks 13, 21, and 34; and ifosfamide IV over 4 hours on days 1-5 of
      weeks 13, 21, 29, and 34. Patients also receive leucovorin calcium and G-CSF as in induction
      therapy. Patients whose tumors are found to over express HER2 (2+ level of expression) also
      receive trastuzumab IV over 30-90 minutes once a week for a total of 34 weeks in addition to
      the chemotherapy regimen.

      Patients are followed monthly for 1 year, every 2 months for 1 year, every 6 months for 2
      years, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 80 patients (40 patients per stratum) will be accrued for this
      study within 2.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date>May 2007</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and safety of treatment assessed using CTC version 2.0</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Descriptive statistics will be utilized to assess feasibility and safety. All toxicities will be carefully monitored. A detailed tabulation of observed toxicities will be made and a qualitative decision on the feasibility will be made.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>Will be estimated with a maximum standard error of no more than 8%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Will be estimated by the Kaplan-Meier method with a maximum standard error of 8%.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Metastatic Osteosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See detailed description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>amethopterin</other_name>
    <other_name>Folex</other_name>
    <other_name>methylaminopterin</other_name>
    <other_name>Mexate</other_name>
    <other_name>MTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV or orally</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo resection</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>irradiation</other_name>
    <other_name>radiotherapy</other_name>
    <other_name>therapy, radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>IFF</other_name>
    <other_name>IFX</other_name>
    <other_name>IPP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
    <other_name>anti-c-erB-2</other_name>
    <other_name>Herceptin</other_name>
    <other_name>MOAB HER2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (combination chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high-grade osteosarcoma

               -  Metastatic

               -  Newly diagnosed

          -  No osteosarcoma arising in areas of Paget's disease or radiotherapy-induced sarcoma

          -  Presenting with at least 1 of the following:

               -  Bone metastases with or without lung metastases

               -  Bilateral lung metastases (any number of nodules)

               -  Unilateral lung metastases with at least 4 nodules

          -  Planned resection of either the primary site or a metastatic site of disease after
             completion of induction therapy

          -  Must be currently enrolled on the tumor biology study COG-P9851

          -  Performance status - ECOG 0-2

          -  Performance status - Karnofsky 50-100% (over age 10)

          -  Performance status - Lansky 50-100% (age 10 and under)

          -  Absolute neutrophil count &gt; 1,000/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Bilirubin ≤ 1.5 times normal

          -  SGPT ≤ 3 times normal

          -  Creatinine ≤ 1.5 times normal

          -  Creatinine clearance or glomerular filtration rate ≥ 70 mL/min

          -  Shortening fraction ≥ 28% by echocardiogram

          -  Ejection fraction ≥ 50% by echocardiogram or MUGA

          -  No history of pericarditis, myocarditis, symptomatic arrhythmia, or conduction
             disturbances

          -  Normal organ function

          -  HIV negative

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No prior chemotherapy

          -  No prior radiotherapy

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ebb</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 1, 2013</last_update_submitted>
  <last_update_submitted_qc>February 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

